Literature DB >> 9423792

Systemic coagulation and fibrinolysis in patients with or at risk for the adult respiratory distress syndrome.

A B Groeneveld1, I Kindt, P G Raijmakers, C E Hack, L G Thijs.   

Abstract

The authors sought to evaluate the pathogenetic and prognostic role of a procoagulant and hypofibrinolytic state in the adult respiratory distress syndrome (ARDS). Twenty-two consecutive patients admitted to the intensive care unit (ICU) for respiratory monitoring (n = 2) or mechanical ventilation (n = 20) were studied, of whom 13 had ARDS and 9 were at risk for the syndrome. Plasma levels of thrombin-antithrombin III complexes (TAT), the plasmin-alpha2-antiplasmin complexes (PAP), tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor type 1 (PAI-1) were measured within 48 h after admission, together with respiratory variables allowing computation of the lung injury score (LIS), and pulmonary microvascular permeability [67Gallium-transferrin pulmonary leak index (PLI)], as measures of pulmonary dysfunction. Blood was also sampled 6-hourly until 2 days after admission. The LIS and PLI were higher in ARDS than at risk patients, in the presence of similar systemic morbidity and mortality. TAT complexes were elevated in a minority of patients of both groups, whereas the PAP, tPA and PAI levels were elevated above normal in the majority of ARDS and at risk patients, but groups did not differ. Neither circulating coagulation nor fibrinolysis variables correlated to either LIS or PLI. Furthermore, the course of haemostatic variables did not relate to outcome. These data indicate that systemic activation of coagulation and impaired fibrinolysis do not play a major role in ARDS development and outcome in patients with acute lung injury.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9423792

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

Review 1.  Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Authors:  Matteo Cesari; Marco Pahor; Raffaele Antonelli Incalzi
Journal:  Cardiovasc Ther       Date:  2010-07-07       Impact factor: 3.023

2.  The procoagulant potential of environmental particles (PM10).

Authors:  P S Gilmour; E R Morrison; M A Vickers; I Ford; C A Ludlam; M Greaves; K Donaldson; W MacNee
Journal:  Occup Environ Med       Date:  2005-03       Impact factor: 4.402

3.  Alveolar plasminogen activator inhibitor-1 predicts ARDS in aspiration pneumonitis.

Authors:  Ali A El Solh; Milapchand Bhora; Lilibeth Pineda; Alan Aquilina; Laurie Abbetessa; Eileen Berbary
Journal:  Intensive Care Med       Date:  2005-11-12       Impact factor: 17.440

4.  Association between urokinase haplotypes and outcome from infection-associated acute lung injury.

Authors:  John Arcaroli; Jeff Sankoff; Nianjun Liu; David B Allison; James Maloney; Edward Abraham
Journal:  Intensive Care Med       Date:  2007-11-10       Impact factor: 17.440

Review 5.  Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome.

Authors:  Robert MacLaren; Kathleen A Stringer
Journal:  Pharmacotherapy       Date:  2007-06       Impact factor: 4.705

Review 6.  Science review: searching for gene candidates in acute lung injury.

Authors:  Dmitry N Grigoryev; James H Finigan; Paul Hassoun; Joe G N Garcia
Journal:  Crit Care       Date:  2004-06-30       Impact factor: 9.097

7.  Recombinant human activated protein C in the treatment of acute respiratory distress syndrome: a randomized clinical trial.

Authors:  Alexander D Cornet; A B Johan Groeneveld; Jorrit J Hofstra; Alexander P Vlaar; Pieter R Tuinman; Arthur van Lingen; Marcel Levi; Armand R J Girbes; Marcus J Schultz; Albertus Beishuizen
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

8.  Orthologous gene-expression profiling in multi-species models: search for candidate genes.

Authors:  Dmitry N Grigoryev; Shwu-Fan Ma; Rafael A Irizarry; Shui Qing Ye; John Quackenbush; Joe G N Garcia
Journal:  Genome Biol       Date:  2004-04-27       Impact factor: 13.583

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.